RE-BVS – Piemonte Repository

Sfoglia per AUTORE
CILLONI D
Collezione ASL Torino 4

Items : 6

Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts. in American journal of hematology / Am J Hematol. 2023 Aug;98(8):E204-E208. doi: 10.1002/ajh.26960. Epub 2023 May 24.

2023
AOU Alessandria
ASL Città di Torino
ASL Torino 4
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara

Della Porta MG; Santini V; Naldi I; Finelli C; Sancetta R; Selleri C; Pasini P; Giordano L; Turrini M; Tosi P; Tanasi I; Frigeni M; Grimaldi D; Marchetti M; Norata M; Galimberti S; Fianchi L; Di Veroli A; Ferrara F; Di Bona E; Bono R; Castelli A; Calvisi A; Rivoli G; Molteni A; Nicolino B; Occhini U; Leuzzi L; Genua A; et alii...

Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS) in Blood

2022
ASL Torino 4
ASL Biella

Lanino L; Salutari P; Perego A; Fattizzo B; Riva M; Ubezio M; Musto P; Cilloni D; Oliva EN; Voso MT; Pelizzari AM; Poloni A; Capodanno I; Elena C; Fozza C; Pane F; Breccia M; De Gobbi M; Di Bassiano F; Barraco D; Crisà E; Ferrero D; Frairia C; Vaccarino A; Griguolo D; Paolini S; Quintini M; Sessa M; Turrini M; et alii...

SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience. in HemaSphere / Hemasphere. 2020 Sep 23;4(5):e483. doi: 10.1097/HS9.0000000000000483. eCollection 2020 Oct.

2020
ASL Torino 4
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
AOU Novara

Tafuri A; Selleri C; Sciumé M; Secchi R; Sarlo C; Rivellini F; Poloni A; Riva M; Pelizzari A; Pilo F; Oliva E; Palumbo GA; Musto P; Niscola P; Messa E; Molteni A; Latagliata R; Mancini S; Gumenyuk S; Frattini F; Guaragna G; Gaidano V; Giai V; Finelli C; Filì C; Fianchi L; Ferrara IL; Fenu S; Di Veroli A; et alii...

Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis. in Cancer medicine / Cancer Med. 2019 Dec;8(18):7567-7576. doi: 10.1002/cam4.2638. Epub 2019 Oct 27.

2019
ASL Torino 4

Balleari E; Filiberti RA; Salvetti C; Allione B; Angelucci E; Bruzzone M; Calzamiglia T; Cavaliere M; Cavalleri M; Cilloni D; Clavio M; Crisà E; Da Col A; Danise P; Pilo F; Ferrero D; Finelli C; Gioia D; Lemoli RM; Masiera E; Messa E; Miglino M; Musto P; Natalie Oliva E; Poloni A; Salvi F; Sanna A; Scudeletti M; Tassara R; et alii...

RWPSS validation in an independent cohort of 946 myelodysplastic syndrome patients from the MDS piedmont registry in Haematologica

2012
ASL Torino 4

Messa E; Gioia D; Salvi F; Allione B; Audisio E; Ferrero D; Crisà E; Lunghi M; Freilone R; Falco P; Cametti G; Bonferroni M; Ciravegna G; Cilloni D; Saglio G; Levis A;

Prognostic value of serum ferritin, transferrin saturation and C-reactive protein at diagnosis in myelodysplastic syndrome patients: Analysis of patients from the MDS piedmont registry in Blood

2011
ASL Torino 4

Messa E; Gioia D; Bertassello C; Ciccone G; Evangelista A; Manuela C; Allione B; Cilloni D; Salvi F; Cametti G; Lunghi M; Ferrero D; Falco P; Bonferroni M; Saglio G; Levis A;